Opioid Settlement Funds Empower Local Solutions: The $50 billion from opioid lawsuits, distributed to states, allows communities to tailor addiction treatment programs to their needs, reflecting conservative values of local control over federal mandates.

AI Diagnostics Transform Healthcare Delivery: The FDA’s approval of an AI tool for early detection of diabetic retinopathy is a game-changer, especially for underserved communities. This private-sector innovation improves screening efficiency and reduces costs. What are your thoughts on AI involvement in healthcare?

#AIDiagnostics #HealthcareInnovation #PatientCare

@HealthReportTV

Vaping-Related Lung Injuries Prompt Calls for Balanced Regulation: A resurgence in vaping-related lung injuries has renewed focus on e-cigarette safety. Targeted regulations, paired with robust public education, can protect health while respecting individual choices.

Encouraging personal responsibility and informed decision-making is key to addressing this issue without overreach. It is also encouraged for parental involvement in decision-making for minors’ potential abuse of vaping.

#VapingHealth #PublicSafety #HealthEducation #youthvape

@HealthReportTV

Alzheimers:
Additional Clinical Trial Details:

• Trial Name and Scope: The TRAILBLAZER-ALZ 2 trial (Phase 3) was a double-blind, placebo-controlled study conducted globally, focusing on early Alzheimer’s patients with confirmed amyloid pathology via PET scans. It built on earlier trials, refining dosing and patient selection.

The trial reported amyloid-related imaging abnormalities (ARIA), including brain swelling (24% of patients) and micro-bleeding (31%), though most cases were mild and resolved over time. Five MRI scans were required to monitor side effects, ensuring patient safety.

Cost and Access: At $32,000 annually, Kisunla is pricier than Leqembi ($26,500), but its limited-duration dosing may reduce overall costs. Medicare covers it for eligible patients, though logistical hurdles like MRI availability could slow adoption.

Ongoing Research: Lilly’s TRAILBLAZER-ALZ 3 (prevention in preclinical AD) and ALZ 5 (enrolling in Korea) trials continue to explore donanemab’s potential, alongside ALZ 6, which investigates ARIA mechanisms and alternative dosing.


Are Alzheimer’s research advances, ongoing trials like TRAILBLAZER-ALZ 3 and 5 explore prevention and broader applications, promising a brighter future? What are your thoughts on balancing innovation with access to life-changing treatments?

@HealthReportTV

FDA Approves Sanofi’s Meningococcal Vaccine: The FDA granted approval for Sanofi’s new meningococcal vaccine

@HealthReportTV

Childhood Obesity Rates Continue to Rise: Description: A CDC report indicates a 5% increase in childhood obesity since 2023, with suggestions for community-based programs to promote healthy lifestyles. Effectiveness of these initiatives is still under evaluation.

@HealthReportTV

Parkinson’s Drug Trial Reports Mixed Outcomes: Description: A new dopamine agonist for Parkinson’s disease is said to have improved motor symptoms in Phase 2 trials but raised concerns about side effects. Additional research is needed to clarify its benefits.

@HealthReportTV

Rural Hospital Closures Impact Care Access: Five rural hospitals are reported to have closed in 2025, potentially creating care deserts. Mobile clinics and other solutions are being considered, with outcomes still uncertain.

@HealthReportTV

Teva’s Celiac Disease Therapy Gains FDA Fast Track Status: Teva’s investigational treatment for celiac disease, aimed at reducing gluten-induced immune responses, is reported to have received FDA Fast Track designation, which may expedite its development. Further studies will clarify its potential.

@HealthReportTV

AbbVie’s Aesthetics Division Announces Staff Reductions: AbbVie’s aesthetics unit, known for Botox, is said to be implementing layoffs due to market challenges in the cosmetic treatment sector. The extent and long-term effects remain under discussion. #HealthcareIndustry #Aesthetics

@HealthReportTV

Modular Medical to Discuss Insulin Patch Pump in Webinar: Modular Medical’s FDA-cleared MODD1 insulin patch pump, designed for user-friendly diabetes management, is set to be featured in a webinar on May 28, 2025, where its affordability and design will reportedly be highlighted. Feedback from users is anticipated. #DiabetesCare #MedicalTechnology

@HEALTHREPORTTV

Medicaid Reforms Spark Debate in Rural Areas: Proposed changes to Medicaid are said to be under discussion, with rural communities reportedly concerned about maintaining care access. Advocates and critics are weighing the potential impacts of reform. #Medicaid #RuralHealthcare

@HealthReportTV

New Insulin Delivery Technology Showcased Today: Modular Medical’s CEO is scheduled to present advancements in insulin delivery technology at a May 28 webinar, reportedly aimed at simplifying diabetes management. The technology’s reach and adoption are yet to be fully evaluated. #DiabetesManagement #HealthTech

@HealthReportTV

Wearable Device for Chronic Pain Cleared by FDA: A wearable neurostimulation device for chronic pain, such as fibromyalgia, is said to have received FDA clearance as a non-opioid treatment option. Its long-term benefits are still under review. #ChronicPain #MedicalDevices

Please share your thoughts and concerns about this!

@HealthReportTV

Low Lung Cancer Screening Rates Raise Concerns: Only 15% of eligible smokers are reportedly receiving recommended low-dose CT scans for lung cancer, prompting discussions about improving outreach and access. Solutions are still being explored. #LungCancer #Screening

@HealthReportTV

Hepatitis C Elimination Efforts Receive Funding Boost: A $500 million allocation is said to have been approved to expand hepatitis C testing and treatment in the U.S., with a goal of elimination by 2030. Progress will depend on implementation strategies. #HepatitisC #PublicHealth

@HealthReportTV

Telemedicine Fraud Targeted by New Measures: Federal authorities are reportedly introducing measures to address telemedicine fraud, focusing on schemes exploiting virtual care platforms. The scope and impact of these efforts are under scrutiny. #Telemedicine #HealthcarePolicy

@HealthReportTV

Hello everyone. This Carolina. I will be managing this channel moving forward. The team is going to focus on our Substack and I will continue to investigate the Medical Industrial Complex and hold them accountable.

My advice to you: I want you to never visit a hospital without instructions to a loved one written down, emailed to your family and a filled out signed notarized power of attorney, additionally you must have a healthcare trusted surrogate ahead of time. Selected some one who you trust with your life and make sure they follow your wishes.

With this said, I am currently in a legal battle to restore Dr. Urso his bodily autonomy and freedom to choose his care and treatments. This has taken a toll on my life since the accusations in court against me are baseless and go against Dr. Urso’s wishes. I plan to continue fighting for his freedom of choice.

I am currently representing myself, but if you know a good lawyer who wants to help me free Dr. Urso please text me at 281-310-0696.

Adaptive Deep Brain Stimulation Approved for Parkinson’s: The FDA is said to have approved adaptive deep brain stimulation (aDBS) for Parkinson’s disease, reportedly using real-time brain monitoring to adjust symptom treatment. Its effectiveness in larger populations is still under evaluation. If you know about this technology and have more information please leave a comment. #Parkinsons #MedicalTechnology

@HealthReportTV

https://fundrazr.com/32YzW1?

DOJ vs Dr. Kirk Moore

Please help this brave doctor who protected his patients at all cost. We need more people to support the Covid heroes. Remember that their sacrifice is still an ongoing battle. Health Report TV no longer supports GiveSendGo or GoFundMe. If you know of a decent fundraising site that stands for our values please comment it below.

@HealthReportTV

Brain-Computer Interface for Stroke Recovery in Trials: Synchron’s stentrode, a brain-computer interface, is reportedly undergoing trials to map brain blood vessels, potentially aiding stroke recovery. Its long-term potential is still under study. #Stroke #MedicalTechnology

@HealthReportTV